AbbVie Inc. (NYSE:ABBV) is one of Best-Performing Pharma Stocks in 2025. AbbVie Inc. (NYSE:ABBV) was downgraded to Peer Perform from Outperform on January 8 by Wolfe Research without a price target. The company said the stock already reflects expectations of outperformance in Skyrizi and Rinvoq, so it is sitting on the sidelines pending greater visibility on the company’s immunology and inflammation “bis” and competitive dynamics.
In a separate development, Reuters reported on January 7 that AbbVie Inc. (NYSE:ABBV) denied involvement in talks to acquire Revolution Medicines. The update came after the Wall Street Journal reported that AbbVie Inc. (NYSE:ABBV) was in advanced talks to buy Revolution Medicines, the cancer drug developer. AbbVie Inc. (NYSE:ABBV) told Reuters in an emailed statement that it is “not in discussions with Revolution Medicines.”
The same day, UBS assumed coverage of AbbVie Inc. (NYSE:ABBV) with a Neutral rating, raising the stock’s price target to $240 from $220. He told investors he believes the company is fairly priced at current levels and sees a balanced risk/reward for the company’s shares as competition emerges for its blockbuster immune drugs Skyrizi and Rinvoq in 2026 and 2027.
AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology and other serious health conditions.
While we recognize ABBV’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 30 stocks that should double in 3 years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published in Internal jumpsuit.